Concepedia

Author

Esther C.W. Breij

Genmab (Netherlands)ORCID

Also Known As

E Breij, E C W Breij, E. Breij, E. C. Breij, E. C. W. Breij, Esther Breij, Esther C W Breij, Esther C. Breij, Esther C. W. Breij, Esther C.W Breij

152

Publications

3K

Citations

24

H-Index

45

Concepts

All Affiliations

Genmab (Netherlands)Leiden University Medical CenterAmsterdam UMC Location Vrije Universiteit AmsterdamGenmab (United States)Vrije Universiteit Amsterdam
EC

About

Esther C.W. Breij is an author at Genmab (Netherlands) specializing in immunology, medicine, and cell biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

9

9

802

2

Immunology

9

9

802

3

Cell Biology

5

5

372

4

Health Sciences

1

1

188

5

Molecular Genetics

1

1

14

Esther C.W. Breij

×

33

Publications

2.9K

Citations

24

H-Index

YearCitations

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

Marije B. Overdijk, Sandra Verploegen, Marijn Bögels,

mAbs

2015

491

Homogeneity of active demyelinating lesions in established multiple sclerosis

Esther C.W. Breij, Bianca P. Brink, Rob Veerhuis,

Annals of Neurology

2008

349

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors

Julia Boshuizen, Louise A. Koopman, Oscar Krijgsman,

Nature Medicine

2018

215

An Antibody–Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors

Esther C.W. Breij, Bart E.C.G. de Goeij, Sandra Verploegen,

Cancer Research

2013

214

The Pathology of Multiple Sclerosis Is Location-Dependent: No Significant Complement Activation Is Detected in Purely Cortical Lesions

Bianca P. Brink, Robert Veerhuis, Esther C.W. Breij,

Journal of Neuropathology & Experimental Neurology

2005

188

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing

Patrick Engelberts, Ida H. Hiemstra, Bart de Jong,

EBioMedicine

2020

159

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

Fabio Da Roit, Patrick Engelberts, Ronald P. Taylor,

Haematologica

2014

145

Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63

Bart E.C.G. de Goeij, Tom Vink, Hendrik ten Napel,

Molecular Cancer Therapeutics

2016

129

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Alexander Muik, Elena Garralda, Friederike Gieseke,

Cancer Discovery

2022

104

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

Hilma J. van der Horst, A. Vera de Jonge, Ida H. Hiemstra,

Blood Cancer Journal

2021

94

Page 1